Cerus Pathogen Inactivation Trial Delay Alters Landscape For Vitex, Navigant

Uncertainty over Baxter/Cerus' Intercept red blood cell pathogen reduction program may benefit competitor Vitex, which is pursuing the same indication for its Inactine device